PIK3CA and breast cancer: We noted the lack of particular clinical or demographic characteristics linked to the presence of the PIK3CA mutation among the patients, which was consistent with other studies [29]; any subset of clinicopathological factors are unlikely to indicate a certain group of patients expected to carry the PIK3CA mutation, indicating that all BC patients should be tested for the PIK3CA gene in order to detect the mutation.